Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ethris GMBH

www.ethris.com

Latest From Ethris GMBH

End Of The Line For AstraZeneca’s Tralokinumab In Asthma

Another Phase III failure looks likely to spell the end for AstraZeneca’s tralokinumab in severe uncontrolled asthma. The company’s eyes are now firmly fixed on benralizumab.

Clinical Trials Respiratory

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie

French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.

Deals M & A

AZ Makes Fresh mRNA Move With Ethris Respiratory Pact

A long-time player in messenger RNA through its partnership with Moderna Therapeutics, AstraZeneca has paid €25m upfront to a German biotech to find targets for investigation in asthma, COPD and idiopathic pulmonary fibrosis.

Deals Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Ethris GMBH
  • Senior Management
  • Carsten Rudolph, PhD, Pres. & CEO
    Michael Kring, CFO
    Christian Plank, PhD, Pres. & CSO
    Gita Dittmar, Head, Corp. Dev.
  • Contact Info
  • Ethris GMBH
    Phone: 89 89 55 788 0
    Semmelweisstr. 3
    Planegg, 82152
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register